Comparative Effectiveness of Upadacitinib and Tofacitinib in Inducing Remission in Ulcerative Colitis: Real-World Data

Clin Gastroenterol Hepatol. 2023 Aug;21(9):2427-2429.e1. doi: 10.1016/j.cgh.2023.03.040. Epub 2023 Apr 7.

Authors

Leo Boneschansker¹, Ashwin N Ananthakrishnan²; Massachusetts General Hospital Crohn’s And Colitis Center Collaborators

Collaborators

Massachusetts General Hospital Crohn’s And Colitis Center Collaborators:
Kristin E Burke, Bharati D Kochar, Emily W Lopes, Hamed Khalili, Francis Colizzo

Affiliations

¹ Massachusetts General Hospital Crohn's and Colitis Center, Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts.
² Massachusetts General Hospital Crohn's and Colitis Center, Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: aananthakrishnan@mgh.harvard.edu.

PMID: 37031712
DOI: 10.1016/j.cgh.2023.03.040

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Colitis, Ulcerative* / drug therapy
Humans
Janus Kinase Inhibitors* / therapeutic use
Piperidines / therapeutic use
Pyrimidines / therapeutic use

Substances

Piperidines
Pyrimidines
tofacitinib
upadacitinib
Janus Kinase Inhibitors

Grants and funding